Indications |
Oral Hypertension Adult: 5-10 mg once daily, increase to 20 mg once daily if necessary. |
Contraindications |
Cardiogenic shock; recent MI or acute unstable angina; severe aortic stenosis. |
Warnings / Precautions |
Hypotension, poor cardiac reserve, heart failure. Sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischemic pain following administration. Pregnancy, lactation. |
Adverse Reactions |
Dizziness; flushing; headache; hypotension; peripheral oedema; tachycardia; palpitations; GI disturbances; increased micturition frequency; lethargy; eye pain; depression; ischaemic chest pain; cerebral or myocardial ischaemia; transient blindness; rashes; fever; abnormal liver function; gingival hyperplasia; myalgia; tremor; impotence. |
Drug Interactions |
Other antihypertensives; aldesleukin; antipsychotics that cause hypotension; may modify insulin and glucose responses; quinidine; carbamazepine; phenytoin; rifampicin; cimetidine; erythromycin. See Below for More cilnidipine Drug Interactions |
Lab Interactions |
Falsely elevated spectrophotometric values of urinary vanillylmandelic acid. |
Mechanism of Actions |
Cilnidipine is a dihydropyridine calcium-channel blocker. It inhibits cellular influx of calcium, thus causing vasodilatation. It has greater selectivity for vascular smooth muscle. It has little or no action at the SA or AV nodes and -ve inotropic activity is rarely seen at therapeutic doses. |
ATC Classification |
C08CA14 - cilnidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases. |
Available As |
|
Cilnidipine
Post Review about Cilnidipine Click here to cancel reply.
Cilnidipine Containing Brands
Cilnidipine is used in following diseases
Drug - Drug Interactions of Cilnidipine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.